Update: Zhongyuan Drops Out of the Bidding
Zhongyuan Union & Cell Engineering Corp (600645: Shanghai) has dropped out of the bidding process for China Cord Blood (CO:US), citing the...
444 Views
Update: Mr. Kam Raises His Stake, and Nanjing Xinjiekou Ups the Pressure
The bidding war for China Cord Blood has heated up. China Cord Blood's Chairman has acquired KKR's 19% stake through a restructured purchase...
388 Views
China Cord Blood: We Love a Crowd
We had previously cited the “going private” offer received by China Cord Blood as an example of the obstacles that minority investors face in...
442 Views
Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder
China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...
441 Views
China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
513 Views